Select your Market
{{ userContent.title }}
Financial results for 2025
Outlook 2026
| 2025 (in € billion) | Change (in %, compared to 2024) | Organic change (in %, compared to 2024) |
|---|---|---|---|
Group net sales | 21.1 | –0.3 | 3.1 |
EBITDA pre | 6.1 | 0.6 | 5.6 |
Life Science sales | 9.0 | 0.7 | 4.0 |
Healthcare sales | 8.6 | 1.8 | 3.7 |
Electronics sales | 3.5 | –7.1 | –0.6 |
“We once again demonstrated our resilience in 2025 in the face of significant geopolitical challenges and strong currency headwinds.”
Our CEO Belén Garijo comments on the full-year 2025 results.
Detailed information about the development of our business for 2025.
Downloads for the Media
Press Releases
The Group delivered on its guidance for 2025 and achieved organic growth despite significant headwinds.
2026/03/05
Our Q4 2025 results will be published on March 5, 2026, at 7 a.m. (CET). Our press conference will take place at 10:00 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Our Q1 2026 results will be published on May 13, 2026, at 7 a.m. (CET). Our conference call for the media will take place at 9:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST).
